<p>马里兰州盖瑟斯堡 --（Newsfile Corp. -2026 年 1 月 13 日）- Shuttle Pharmaceuticals Holdings, Inc.（&#34;Shuttle Pharma&#34;或&#34;公司&#34;）对犹他州表示赞赏，该州成为美国第一个允许人工智能系统在没有直接医生参与的情况下授权处方续药的州——这一监管首创标志着人工智能如何开始降低医疗成本、消除延误并扩大医疗服务的可及性。</p>
<p>该试点项目通过犹他州人工智能政策办公室启动，由 Doctronic 提供支持，允许人工智能为慢性病患者续药某些常见处方药。支持者认为，这一模式为患者节省了时间和金钱，特别是在医生短缺的农村地区，常规续药可能导致数周的延误和昂贵的诊所就诊。</p>
<p>虽然仅限于续药并受到严格监管，但该倡议反映了医疗保健领域的更广泛转变：人工智能被信任用于自动化重复的、高容量的决策——使人类专家能够专注于复杂的、高价值的工作。</p>
<p>这一原则正是我们相信 Shuttle Pharma 的 Molecule.ai 平台在药物发现中所构建的核心。</p>
<p>自动化那些耗时且昂贵的瓶颈</p>
<p>在临床护理中，处方续药耗时、昂贵且往往是多余的。在药物开发中，类似的瓶颈在开发过程的早期就会出现——在分子筛选、候选药物优先级排序以及失败的后期实验中，这些实验往往代价高昂。</p>
<p>Molecule.ai 应用人工智能来最小化这些低效，显著减少：</p>
<ul>
<li>确定可行药物候选者的时间；</li>
<li>失败实验和后期流失的成本；以及</li>
<li>人力在重复筛选和分析上花费的时间。</li>
</ul>
<p>Molecule.ai 平台利用先进的 Agentic AI 来预测分子特性、建模药物 - 靶点相互作用，并在化合物进入实验室之前优先考虑它们。我们相信，以前需要数月的手动实验现在可以缩短到几天——成本也大幅降低。</p>
<p>正如犹他州的人工智能续药系统自动化常规处方决策一样，Molecule.ai 自动化了药物发现中最资源密集的步骤，使科学家能够专注于突破性的创新，而不是试错。</p>
<p><strong>为规模、安全和监管而构建</strong></p>
<p>犹他州试点项目的批评者警告说，人工智能可能会错过微妙的警告信号或被滥用。这些担忧突显了一个核心真理：人工智能的设计不仅要追求速度，还要追求问责。</p>
<p>Molecule.ai 通过嵌入以下内容来解决这些担忧：</p>
<ul>
<li>不确定性量化，以便标记低置信度的预测</li>
<li>人工干预工作流程，确保在关键决策点有专家监督</li>
<li>可解释模型，使团队能够理解为何某个分子被优先考虑</li>
</ul>
<p>这与犹他州的监管沙箱方法相呼应，在该方法中，人工智能被允许在明确的边界内运作，将边缘案例升级到人类，并在更广泛的采用之前证明其安全性。</p>
<p>人工智能在医疗保健和药物发现中的经济案例</p>
<p>医疗保健和生物制药行业面临相同的经济现实：成本上升、人力资源有限和需求增长。我们相信人工智能可以提供可持续发展的路径。</p>
<ul>
<li>对于患者，我们相信人工智能可以减少不必要的就诊、等待时间和自付费用。</li>
<li>对于医疗系统，我们相信人工智能可以降低运营负担并改善可及性。</li>
<li>对于药物开发者，我们相信人工智能可以缩短研发时间，减少资本消耗，并提高临床成功的概率。</li>
</ul>
<p>Molecule.ai 旨在大规模提供这些节省——将人工智能从研究工具转变为现代药物开发的核心基础设施。</p>
<p><strong>未来的展望</strong></p>
<p>犹他州官员表示，人工智能处方试点的结果将有助于塑造未来的州和联邦人工智能政策，可能成为医疗保健中高风险人工智能监管的国家模型。</p>
<p>随着监管者越来越习惯于在明显节省时间和金钱而不牺牲安全性的情况下授予人工智能有限的权力，行业将越来越需要强大、可审计和经济转型的人工智能平台。</p>
<p>这就是 Shuttle Pharma 通过 Molecule.ai 平台所构建的未来：</p>
<p>加速发现、降低成本，并更快地为患者带来更好的疗法——安全且负责任。</p>
<p><strong>关于 Shuttle Pharma</strong></p>
<p>Shuttle Pharmaceuticals Holdings, Inc.拥有一个基于人工智能（&#34;AI&#34;）的药物发现和早期药物开发平台。通过将现代人工智能技术与结构化科学工作流程相结合，Molecule.ai 平台帮助研究人员更高效地探索化学空间，以更清晰的方式评估分子想法，并在药物开发的最早阶段做出更明智的决策。</p>
<p>关于前瞻性声明的警示说明</p>
<p>本新闻稿中关于未来预期、计划和前景的声明，以及关于非历史事实事项的其他声明，可能构成 “前瞻性声明”。这些声明包括但不限于关于我们公司及 Molecule.ai 平台发展的声明。诸如 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将会”、“会” 等类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果存在重大差异，包括在 Shuttle Pharma 截至 2024 年 12 月 31 日的年度报告的 “风险因素” 部分中讨论的因素，以及其他 SEC 文件中提到的因素。本新闻稿中包含的任何前瞻性声明仅在本日期有效，除非联邦证券法要求，Shuttle Pharma 不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>Shuttle Pharmaceuticals</strong></p>
<p>Chris Cooper</p>
<p>首席执行官</p>
<p>info@shuttlepharma.com</p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/280266</p>

SHPH

<p>犹他州成为美国首个允许人工智能系统在没有直接医生参与的情况下授权处方续药的州，旨在降低医疗成本并改善获取医疗服务的机会。Shuttle Pharmaceuticals 的 Molecule.ai 平台应用人工智能来简化药物发现，最大限度地减少与药物开发相关的低效和成本。该倡议反映了医疗保健领域向自动化常规决策的更广泛趋势，同时通过专家监督确保问责和安全。试点项目的结果可能会影响未来医疗保健领域的人工智能监管，推动人工智能作为药物开发的变革性工具</p>

<p>Gaithersburg, Maryland--(Newsfile Corp. - January 13, 2026) - Shuttle Pharmaceuticals Holdings, Inc.  (&#34;Shuttle Pharma&#34; or the &#34;Company&#34;), applauds the state of Utah which has become the first state in the United States to allow artificial intelligence systems to authorize prescription refills without direct physician involvement — a regulatory first that signals how AI is beginning to reduce healthcare costs, eliminate delays, and expand access to care.</p>
<div class="lb-trans"><p>马里兰州盖瑟斯堡 --（Newsfile Corp. -2026 年 1 月 13 日）- Shuttle Pharmaceuticals Holdings, Inc.（&#34;Shuttle Pharma&#34;或&#34;公司&#34;）对犹他州表示赞赏，该州成为美国第一个允许人工智能系统在没有直接医生参与的情况下授权处方续药的州——这一监管首创标志着人工智能如何开始降低医疗成本、消除延误并扩大医疗服务的可及性。</p>
</div><p>The pilot program, launched through Utah's Office of Artificial Intelligence Policy and powered by Doctronic, allows AI to refill certain commonly prescribed medications for chronic conditions. Proponents argue that the model saves patients time and money, particularly in rural areas where physician shortages can turn routine refills into weeks-long delays and costly clinic visits.</p>
<div class="lb-trans"><p>该试点项目通过犹他州人工智能政策办公室启动，由 Doctronic 提供支持，允许人工智能为慢性病患者续药某些常见处方药。支持者认为，这一模式为患者节省了时间和金钱，特别是在医生短缺的农村地区，常规续药可能导致数周的延误和昂贵的诊所就诊。</p>
</div><p>While limited to refills and governed by strict oversight, the initiative reflects a broader shift across healthcare: AI is being trusted to automate repetitive, high-volume decisions — freeing human experts to focus on complex, high-value work.</p>
<div class="lb-trans"><p>虽然仅限于续药并受到严格监管，但该倡议反映了医疗保健领域的更广泛转变：人工智能被信任用于自动化重复的、高容量的决策——使人类专家能够专注于复杂的、高价值的工作。</p>
</div><p>That same principle is at the core of what we believe Shuttle Pharma's Molecule.ai platform is building in drug discovery.</p>
<div class="lb-trans"><p>这一原则正是我们相信 Shuttle Pharma 的 Molecule.ai 平台在药物发现中所构建的核心。</p>
</div><p>Automating the Bottlenecks That Cost Time and Money</p>
<div class="lb-trans"><p>自动化那些耗时且昂贵的瓶颈</p>
</div><p>In clinical care, prescription refills are time-consuming, expensive, and often redundant. In drug development, similar bottlenecks occur much earlier in the development process — during molecular screening, during candidate prioritization, and during failed late-stage experiments that are costly.</p>
<div class="lb-trans"><p>在临床护理中，处方续药耗时、昂贵且往往是多余的。在药物开发中，类似的瓶颈在开发过程的早期就会出现——在分子筛选、候选药物优先级排序以及失败的后期实验中，这些实验往往代价高昂。</p>
</div><p>Molecule.ai applies AI to minimize these inefficiencies by dramatically reducing:</p>
<div class="lb-trans"><p>Molecule.ai 应用人工智能来最小化这些低效，显著减少：</p>
</div><ul>
<li>Time to identify viable drug candidates;</li>
<li>Cost of failed experiments and late-stage attrition; and</li>
<li>Human labor spent on repetitive screening and analysis.</li>
</ul>
<div class="lb-trans"><ul>
<li>确定可行药物候选者的时间；</li>
<li>失败实验和后期流失的成本；以及</li>
<li>人力在重复筛选和分析上花费的时间。</li>
</ul>
</div><p>The Molecule.ai platform leverages advanced Agentic AI to predict molecular properties, model drug-target interactions and prioritize compounds before they ever reach the lab. We believe that what once required months of manual experimentation could now be narrowed to days — at a fraction of the cost.</p>
<div class="lb-trans"><p>Molecule.ai 平台利用先进的 Agentic AI 来预测分子特性、建模药物 - 靶点相互作用，并在化合物进入实验室之前优先考虑它们。我们相信，以前需要数月的手动实验现在可以缩短到几天——成本也大幅降低。</p>
</div><p>Just as Utah's AI refill system automates routine prescribing decisions, Molecule.ai automates the most resource-intensive steps of drug discovery, allowing scientists to focus on breakthrough innovation rather than trial-and-error.</p>
<div class="lb-trans"><p>正如犹他州的人工智能续药系统自动化常规处方决策一样，Molecule.ai 自动化了药物发现中最资源密集的步骤，使科学家能够专注于突破性的创新，而不是试错。</p>
</div><p><strong>Built for Scale, Safety, and Oversight</strong></p>
<div class="lb-trans"><p><strong>为规模、安全和监管而构建</strong></p>
</div><p>Critics of Utah's pilot program warn that AI could miss subtle warning signs or be misused. These concerns highlight a central truth: AI must be designed not only for speed, but for accountability.</p>
<div class="lb-trans"><p>犹他州试点项目的批评者警告说，人工智能可能会错过微妙的警告信号或被滥用。这些担忧突显了一个核心真理：人工智能的设计不仅要追求速度，还要追求问责。</p>
</div><p>Molecule.ai addresses these concerns by embedding:</p>
<div class="lb-trans"><p>Molecule.ai 通过嵌入以下内容来解决这些担忧：</p>
</div><ul>
<li>Uncertainty quantification, so low-confidence predictions are flagged</li>
<li>Human-in-the-loop workflows, ensuring expert oversight at critical decision points</li>
<li>Explainable models, enabling teams to understand why a molecule is prioritized</li>
</ul>
<div class="lb-trans"><ul>
<li>不确定性量化，以便标记低置信度的预测</li>
<li>人工干预工作流程，确保在关键决策点有专家监督</li>
<li>可解释模型，使团队能够理解为何某个分子被优先考虑</li>
</ul>
</div><p>This mirrors Utah's regulatory sandbox approach, where AI is allowed to operate within clear boundaries, escalate edge cases to humans, and demonstrate safety before wider adoption.</p>
<div class="lb-trans"><p>这与犹他州的监管沙箱方法相呼应，在该方法中，人工智能被允许在明确的边界内运作，将边缘案例升级到人类，并在更广泛的采用之前证明其安全性。</p>
</div><p>The Economic Case for AI in Healthcare and Drug Discovery</p>
<div class="lb-trans"><p>人工智能在医疗保健和药物发现中的经济案例</p>
</div><p>The healthcare and biopharmaceutical industries face the same economic reality: rising costs, limited human resources, and growing demand. We believe AI can offer a path to sustainability.</p>
<div class="lb-trans"><p>医疗保健和生物制药行业面临相同的经济现实：成本上升、人力资源有限和需求增长。我们相信人工智能可以提供可持续发展的路径。</p>
</div><ul>
<li>For patients, we believe AI can reduce unnecessary visits, wait times, and out-of-pocket costs.</li>
<li>For healthcare systems, we believe AI lowers operational burden and improves access.</li>
<li>For drug developers, we believe AI can cut R&amp;D timelines, reduce capital burn, and increase the probability of clinical success.</li>
</ul>
<div class="lb-trans"><ul>
<li>对于患者，我们相信人工智能可以减少不必要的就诊、等待时间和自付费用。</li>
<li>对于医疗系统，我们相信人工智能可以降低运营负担并改善可及性。</li>
<li>对于药物开发者，我们相信人工智能可以缩短研发时间，减少资本消耗，并提高临床成功的概率。</li>
</ul>
</div><p>Molecule.ai is designed to deliver these savings at scale — transforming AI from a research tool into core infrastructure for modern drug development.</p>
<div class="lb-trans"><p>Molecule.ai 旨在大规模提供这些节省——将人工智能从研究工具转变为现代药物开发的核心基础设施。</p>
</div><p><strong>A Glimpse of the Future</strong></p>
<div class="lb-trans"><p><strong>未来的展望</strong></p>
</div><p>Utah officials have said results from the AI prescription pilot will help shape future state and federal AI policy, potentially serving as a national model for high-stakes AI regulation in healthcare.</p>
<div class="lb-trans"><p>犹他州官员表示，人工智能处方试点的结果将有助于塑造未来的州和联邦人工智能政策，可能成为医疗保健中高风险人工智能监管的国家模型。</p>
</div><p>As regulators grow more comfortable granting AI limited authority where it demonstrably saves time and money without sacrificing safety, the industry will increasingly demand AI platforms that are robust, auditable, and economically transformative.</p>
<div class="lb-trans"><p>随着监管者越来越习惯于在明显节省时间和金钱而不牺牲安全性的情况下授予人工智能有限的权力，行业将越来越需要强大、可审计和经济转型的人工智能平台。</p>
</div><p>That is the future Shuttle Pharma is building toward with the Molecule.ai platform:</p>
<div class="lb-trans"><p>这就是 Shuttle Pharma 通过 Molecule.ai 平台所构建的未来：</p>
</div><p>AI that accelerates discovery, lowers costs, and brings better therapies to patients faster — safely and responsibly.</p>
<div class="lb-trans"><p>加速发现、降低成本，并更快地为患者带来更好的疗法——安全且负责任。</p>
</div><p><strong>About Shuttle Pharma</strong></p>
<div class="lb-trans"><p><strong>关于 Shuttle Pharma</strong></p>
</div><p>Shuttle Pharmaceuticals Holdings, Inc.  owns a pharmaceutical software artificial intelligence (&#34;AI&#34;) driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.</p>
<div class="lb-trans"><p>Shuttle Pharmaceuticals Holdings, Inc.拥有一个基于人工智能（&#34;AI&#34;）的药物发现和早期药物开发平台。通过将现代人工智能技术与结构化科学工作流程相结合，Molecule.ai 平台帮助研究人员更高效地探索化学空间，以更清晰的方式评估分子想法，并在药物开发的最早阶段做出更明智的决策。</p>
</div><p>Cautionary Note Regarding Forward-Looking Statements</p>
<div class="lb-trans"><p>关于前瞻性声明的警示说明</p>
</div><p>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward-looking statements.&#34; These statements include, but are not limited to, statements concerning the development of our company and the Molecule.ai platform. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the &#34;Risk Factors&#34; section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿中关于未来预期、计划和前景的声明，以及关于非历史事实事项的其他声明，可能构成 “前瞻性声明”。这些声明包括但不限于关于我们公司及 Molecule.ai 平台发展的声明。诸如 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将会”、“会” 等类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果存在重大差异，包括在 Shuttle Pharma 截至 2024 年 12 月 31 日的年度报告的 “风险因素” 部分中讨论的因素，以及其他 SEC 文件中提到的因素。本新闻稿中包含的任何前瞻性声明仅在本日期有效，除非联邦证券法要求，Shuttle Pharma 不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Shuttle Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>Shuttle Pharmaceuticals</strong></p>
</div><p>Chris Cooper</p>
<div class="lb-trans"><p>Chris Cooper</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>info@shuttlepharma.com</p>
<div class="lb-trans"><p>info@shuttlepharma.com</p>
</div><p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280266</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/280266</p>
</div>

犹他州批准了人工智能处方药。人工智能如何节省时间、降低成本——以及为什么 Molecule.ai 的药物发现平台现在比以往任何时候都更重要